Evidence map›Paper›PMID 28545715›Full record

ArticleKidney international2017

APOL1 genetic variants are not associated with longitudinal blood pressure in young black adults.

Teresa K Chen, Michelle M Estrella, Eric Vittinghoff, Feng Lin, Orlando M Gutierrez, Holly Kramer, Cora E Lewis, Jeffrey B Kopp, Norrina B Allen, Cheryl A Winkler and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Kidney international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Kidney international reports · 2025
    Article
  3. Article
  4. Association ofJournal of the American Heart Association · 2020
    Article
  5. Genetics and ESKD Disparities in African Americans.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Review
  6. Review
  7. Ten years in: APOL1 reaches beyond the kidney.Current opinion in nephrology and hypertension · 2019
    Review
  8. Review
  9. The Impact of APOL1 on Chronic Kidney Disease and Hypertension.Advances in chronic kidney disease · 2019
    Review
  10. Article
  11. Observational
  12. Circulation. Genomic and precision medicine · 2018
    Article
  13. Apolipoprotein L1 nephropathies: 2017 in review.Current opinion in nephrology and hypertension · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Teresa K ChenDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: tchen39@jhmi.edu.
Michelle M EstrellaKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, California, USA; San Francisco VA Medical Center, San Francisco, California, USA.
Eric VittinghoffDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Feng LinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Orlando M GutierrezDivision of Preventative Medicine, Department of Medicine, University of Alabama at Birmingham, Alabama, USA.
Holly KramerDivision of Nephrology, Department of Medicine, Loyola University, Maywood, Illinois, USA.
Cora E LewisDivision of Preventative Medicine, Department of Medicine, University of Alabama at Birmingham, Alabama, USA.
Jeffrey B KoppKidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
Norrina B AllenDivision of Epidemiology, Department of Preventative Medicine, Northwestern University, Chicago, Illinois, USA.
Cheryl A WinklerBasic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health and Leidos Biomedical Research, Frederick National Laboratory, Frederick, Maryland, USA.
Kirsten B Bibbins-DomingoKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, California, USA.
Carmen A PeraltaKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, California, USA; San Francisco VA Medical Center, San Francisco, California, USA.
University of California, San Francisco · USUniversity of Alabama at Birmingham · USJohns Hopkins University · USLoyola University Chicago · USNational Cancer Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNorthwestern University · US

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Focal Segmental Glomerulosclerosis: Genetics & MechanismsZIADK043308 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KOPP, JEFFREY BURNETT · 2009 to 2024
$15.7M
Genetics of Renal Disease in African AmericansZIABC010022 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WINKLER, CHERYL · 2009 to 2022
$8.9M
A Triple Marker Approach To Optimize CKD Detection Among Black and White AdultsR03DK095877 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI PERALTA, CARMEN ALICIA · 2012 to 2014
$514k
NHLBI NIH HHS HHSN268200900041CNHLBI NIH HHS HHSN268201300025CNHLBI NIH HHS HHSN268201300026CNHLBI NIH HHS HHSN268201300027CNHLBI NIH HHS HHSN268201300028CNHLBI NIH HHS HHSN268201300029CNIDDK NIH HHS P30 DK079626NIDDK NIH HHS R03 DK095877
6 · The paper itself

Abstract

Whether APOL1 polymorphisms contribute to the excess risk of hypertension among blacks is unknown. To assess this we evaluated whether self-reported race and, in blacks, APOL1 risk variants (high-risk [2 risk alleles] versus low-risk [0-1 risk allele]) were associated with longitudinal blood pressure. Blood pressure trajectories were determined using linear mixed-effects (slope) and latent class models (5 distinct groups) during 25 years of follow-up in the Coronary Artery Risk Development in Young Adults Study. Associations of race and APOL1 genotypes with blood pressure change, separately, using linear mixed-effects and multinomial logistic regression models, adjusting for demographic, socioeconomic, and traditional hypertension risk factors, anti-hypertensive medication use, and kidney function were evaluated. Among 1700 whites and 1330 blacks (13% APOL1 high-risk, mean age 25 years; 46% male) mean mid-, ([systolic + diastolic blood pressure]/2), systolic, and diastolic blood pressures were 89, 110, and 69 mm Hg, respectively. One percent of participants used anti-hypertensive medications at baseline. Compared to whites, blacks, regardless of APOL1 genotype, had significantly greater increases in mid-blood pressure and were more likely to experience significantly increasing mid-blood pressure trajectories with adjusted relative risk ratios of 5.21 and 7.27 for moderate-increasing and elevated-increasing versus low-stable blood pressure, respectively. Among blacks, longitudinal mid-blood pressure changes and mid-blood pressure trajectory classification were similar by APOL1 risk status. Modeling systolic and diastolic blood pressure as outcomes yielded similar findings. From young adulthood to mid-life, blacks have greater blood pressure increases versus whites that are not fully explained by traditional risk factors. Thus APOL1 variants are not associated with longitudinal blood pressure in blacks.

Indexed as

Apolipoprotein L1Blood PressureHypertensionAdultAllelesAntihypertensive AgentsBlack or African AmericanBlood Pressure DeterminationFemaleFollow-Up StudiesGenotyping TechniquesHumansLongitudinal StudiesMaleModels, BiologicalPolymorphism, GeneticAntihypertensive AgentsAPOL1 protein, humanApolipoprotein L1APOL1apolipoprotein L1blood pressureCARDIAhypertension

Identifiers

PMID28545715
PMCPMC5610603
OpenAlexW2618645196

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.